ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

ADVFN

Trade Now

EasyMarkets
Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P 500
4,565.68
(
0.24%
)
US Tech 100
15,643.60
(
0.23%
)
Dow Jones
35,555.26
(
0.39%
)
Brent Oil
82.605
(
1.39%
)
Bitcoin
37,839.59
(
0.00%
)
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Gamida Cell Ltd (GMDA)

  7. Gamida Cell Ltd (GMDA) News

GMDA Gamida Cell Ltd

0.3299
-0.0071 (-2.11%)
Last Updated: 13:40:53
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Gamida Cell Ltd GMDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
Upgrade Icon
-0.0071 -2.11% 0.3299 13:40:53
Open Price Low Price High Price Close Price Prev Close
0.336 0.3089 0.34 0.337
more quote information »

Recent News

Date Time Source Heading
11/24/202316:15EDGAR2Form 8-K - Current report
11/20/202317:27EDGAR2Form SC 13D/A - General statement of acquisition of..
11/15/202317:24EDGAR2Form S-3 - Registration statement under Securities Act of..
11/15/202307:00EDGAR2Form 8-K - Current report
11/14/202307:00GLOBEGamida Cell Reports Third Quarter 2023 Financial Results and..
11/08/202316:05EDGAR2Form SC 13D/A - General statement of acquisition of..
10/20/202316:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/20/202316:39EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
10/20/202316:01EDGAR2Form 8-K - Current report
10/11/202307:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/02/202316:01EDGAR2Form SC 13D/A - General statement of acquisition of..
9/29/202308:41EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
9/27/202316:43EDGAR2Form 8-K - Current report
9/13/202316:01EDGAR2Form DEF 14A - Other definitive proxy statements
9/01/202316:08EDGAR2Form PRE 14A - Other preliminary proxy statements
8/21/202317:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
8/15/202316:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/15/202316:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
8/14/202316:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/14/202307:30EDGAR2Form 8-K - Current report
7/11/202308:00BWData Published in Transplantation and Cellular Therapy..
7/10/202314:00PRNUSSTAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE..
6/14/202316:30BWGamida Cell To Host Investor Day
5/31/202316:30BWGamida Cell to Present Corporate Highlights at the Jefferies..
5/31/202307:00BWData To Be Presented on Gamida Cell Natural Killer (NK) Cell..
5/22/202308:00BWGamida Cell Appoints Terry Coelho as CFO
5/15/202316:05BWGamida Cell Reports First Quarter 2023 Financial Results and..
5/11/202317:20BWGamida Cell Announces the Date of Its First Quarter 2023..
4/19/202308:15BWGamida Cell Announces Pricing of $23 Million Public Offering..
4/18/202319:16BWGamida Cell Announces Launch of Public Offering of..
4/17/202316:16BWGamida Cell’s Allogeneic Cell Therapy Omisirge®..
4/17/202314:30DJNGamida Cell Shares Up 34% on FDA Approval of Omisirge Cell..
3/27/202307:00BWGamida Cell Reports Full Year 2022 Financial Results and..
3/20/202316:30BWGamida Cell Announces Changes to Board of Directors
3/20/202308:00BWGamida Cell Announces the Date of Its Fourth Quarter and..
3/07/202308:00BWGamida Cell to Present Corporate Highlights at the..
2/18/202312:30BWData Presented on Gamida Cell’s Omidubicel, GDA-201 at the..
12/12/202213:11TRMNAnalysts’ Top Healthcare Picks: Crispr Therapeutics AG..
12/12/202207:00BWGamida Cell Announces Closing of $25 Million Financing With..

Your Recent History

NASDAQ
GMDA
Gamida Cell

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com